Seung-Yong Seong

Seung-Yong Seong

Company: Shaperon Inc.

Job title: Professor, Department of Microbiology & Immunology & Co- CEO


Randomized Double-Blind, Placebo- Controlled Phase 2 Trial of NuGel, an Inflammasome Inhibitor, for Atopic Dermatitis 12:00 pm

A novel inflammasome inhibitor targeting GPCR19 GPCR19-P2X7R complex regulating NLRP3 inflammasome Efficient regulation of clinical symptoms assessed by EASI scoreRead more

day: Day 2 - Track B - Morning

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.